Nexvet Biopharma PLC (NASDAQ:NVET)’s share price dropped 6.6% during mid-day trading on Tuesday . The company traded as low as $5.00 and last traded at $5.09, with a volume of 59,863 shares traded. The stock had previously closed at $5.45.

NVET has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Nexvet Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Thursday, June 16th. Credit Suisse Group AG reiterated a “buy” rating on shares of Nexvet Biopharma PLC in a research report on Saturday, May 14th.

The stock’s 50-day moving average is $5.10 and its 200 day moving average is $3.73. The firm’s market capitalization is $61.86 million.

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.